ProductsBack/NK1.1 antibody [PK136]

NK1.1 antibody [PK136]

Name: NK1.1 antibody [PK136]
SKU: GTX01478_G10
Availability: BackOrder

GTX01478

ApplicationsFlow Cytometry, ImmunoPrecipitation, ImmunoHistoChemistry, ImmunoHistoChemistry Frozen, ImmunoHistoChemistry Paraffin, Neutralisation/Blocking, Other Application

Product group Antibodies

TargetKlrb1c

Overview

Supplier
GeneTex
Product Name
NK1.1 antibody [PK136]
Delivery Days Customer
9
Application Supplier Note
*Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
Applications
Flow Cytometry, ImmunoPrecipitation, ImmunoHistoChemistry, ImmunoHistoChemistry Frozen, ImmunoHistoChemistry Paraffin, Neutralisation/Blocking, Other Application
Certification
Research Use Only
Clonality
Monoclonal
Clone ID
PK136
Concentration
0.5 mg/ml
Conjugate
Unconjugated
Gene ID17059
Target name
Klrb1c
Target description
killer cell lectin-like receptor subfamily B member 1C
Target synonyms
CD161, Klrb1b, Ly-59, Ly55c, Ly59, NK-RP1, NK1.1, NKR-P1.9, NKRP1, NKRP140, Nk-1, Nk-1.2, Nk1, Nk1.2, Nkrp1b, Nkrp1c, ly-55c, killer cell lectin-like receptor subfamily B member 1C, CD161 antigen-like family member C, NKR-P1 40, NKR-P1B, killer cell lectin-like receptor subfamily A member 1C, lymphocyte antigen 55 complex, locus C, lymphocyte antigen 55c, lymphocyte antigen 59, natural killer cell receptor protein NKR-P1C, natural killer cell receptor-P1, natural killer cell surface protein P1-40, natural killer cell-associated antigen 1
Host
Mouse
Isotype
IgG2a
Protein IDP27814
Protein Name
Killer cell lectin-like receptor subfamily B member 1C
Storage Instruction
2°C to 8°C
UNSPSC
12352203

References

Lin X, Zeng T, Xiong J, et al. Combined α-programmed death-1 monoclonal antibody blockade and fractionated radiation therapy reduces tumor growth in mouse EL4 lymphoma. Cancer Biol Ther. 2019,20(5):666-679. doi: 10.1080/15384047.2018.1550569
Read this paper
Mukherjee S, Fried A, Hussaini R, et al. Phytosomal curcumin causes natural killer cell-dependent repolarization of glioblastoma (GBM) tumor-associated microglia/macrophages and elimination of GBM and GBM stem cells. J Exp Clin Cancer Res. 2018,37(1):168. doi: 10.1186/s13046-018-0792-5
Read this paper
Krebs DL, Chehal MK, Sio A, et al. Lyn-dependent signaling regulates the innate immune response by controlling dendritic cell activation of NK cells. J Immunol. 2012,188(10):5094-105. doi: 10.4049/jimmunol.1103395
Read this paper
Diamond MS, Kinder M, Matsushita H, et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med. 2011,208(10):1989-2003. doi: 10.1084/jem.20101158
Read this paper
Lubinski JM, Lazear HM, Awasthi S, et al. The herpes simplex virus 1 IgG fc receptor blocks antibody-mediated complement activation and antibody-dependent cellular cytotoxicity in vivo. J Virol. 2011,85(7):3239-49. doi: 10.1128/JVI.02509-10
Read this paper
Awasthi A, Samarakoon A, Chu H, et al. Rap1b facilitates NK cell functions via IQGAP1-mediated signalosomes. J Exp Med. 2010,207(9):1923-38. doi: 10.1084/jem.20100040
Read this paper
Coudert JD, Scarpellino L, Gros F, et al. Sustained NKG2D engagement induces cross-tolerance of multiple distinct NK cell activation pathways. Blood. 2008,111(7):3571-8. doi: 10.1182/blood-2007-07-100057
Read this paper
Ljutic B, Carlyle JR, Filipp D, et al. Functional requirements for signaling through the stimulatory and inhibitory mouse NKR-P1 (CD161) NK cell receptors. J Immunol. 2005,174(8):4789-96.
Read this paper
Kanwar JR, Shen WP, Kanwar RK, et al. Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy. J Natl Cancer Inst. 2001,93(20):1541-52.
Read this paper

Datasheet

Download Datasheet

FAQ

Go to our frequently asked questions

NK1.1 antibody [PK136]

Large volume orders?

Overview

References

Datasheet

FAQ

Related products